LONDON A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business.
- Express Scripts staking out million dollar gene therapies
- China's Liaoning culls more than 8,000 hogs after African swine fever outbreak
- Trump administration sued over Arkansas' Medicaid work requirements
- New York sues OxyContin maker Purdue Pharma over opioids
- Monsanto Roundup appeal has uphill climb on 'junk science' grounds: legal experts
GOMA, Democratic Republic of Congo/GENEVA Democratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak.
(Reuters Health) - People who have traumatic brain injuries may be nearly twice as likely to die by suicide as individuals who don't have a history of injuries like concussions and skull fractures, a large Danish study suggests.
(Reuters Health) - After sex, men can sometimes experience a myriad of confusing negative feelings, a phenomenon called post-coital dysphoria (PCD), which can interfere with relationships, researchers say.
(Reuters Health) - When people take daily pills to minimize their chances of getting HIV, they are also more likely to get routine care like flu shots and recommended screenings for common health problems, a U.S. study suggests.